科济药业再涨超3%子公司申报的舒瑞基奥仑赛注射液拟纳入优先审评

动脉网
22 May

科济药业-B股价再涨超3%,近一个月翻倍。其子公司恺兴生命科技的舒瑞基奥仑赛注射液拟纳入优先审评,治疗晚期胃/食管胃结合部腺癌,标志着CAR-T疗法在实体瘤领域的重大进展。该药物在临床试验中疗效显著且安全,已获多项资格认定。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10